Search research articles
Contact Us
Filters
Showing results (251-260 of 703) with videos related to
Page
of 71
Sort By:
Future Oncology (London, England)
|
July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
Nikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Immuno-Oncology Technology
|
November 24, 2025
Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients
I A Vergara, S N Lo, I Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients
Matteo S Carlino, Carina Fung, Hamideh Shahheydari, et al.
Molecular Cancer Therapeutics
|
May 7, 2013
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
Matteo S Carlino, Kavitha Gowrishankar, Catherine A B Saunders, et al.
Journal for Immunotherapy of Cancer
|
November 25, 2020
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
Kazi J Nahar, Robert V Rawson, Tasnia Ahmed, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2022
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF<sup>V600</sup> wild-type melanoma progressing on prior anti-programmed death-1 therapy
Shahneen Sandhu, Victoria Atkinson, Maria González Cao, et al.
Molecular Cancer
|
October 11, 2024
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response
Su Yin Lim, Ines Pires da Silva, Nurudeen A Adegoke, et al.
Clinical and Experimental Dermatology
|
April 18, 2022
Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge and behaviour of Australian high-school students towards sun safety: a prospective study
Sarah Hanna, Emmanuel Marinos, Derek Bryan, et al.
Histopathology
|
December 28, 2018
Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment
Tuba N Gide, Benjamin M Allanson, Alexander M Menzies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
Georgina V Long, Alexander M Menzies, Adnan M Nagrial, et al.
Page
of 71
Search research articles
Search
Showing results (251-260 of 703) with videos related to
Sort By:
Page
of 71
Future Oncology (London, England)
|
July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
Nikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Immuno-Oncology Technology
|
November 24, 2025
Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients
I A Vergara, S N Lo, I Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients
Matteo S Carlino, Carina Fung, Hamideh Shahheydari, et al.
Molecular Cancer Therapeutics
|
May 7, 2013
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
Matteo S Carlino, Kavitha Gowrishankar, Catherine A B Saunders, et al.
Journal for Immunotherapy of Cancer
|
November 25, 2020
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
Kazi J Nahar, Robert V Rawson, Tasnia Ahmed, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2022
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF<sup>V600</sup> wild-type melanoma progressing on prior anti-programmed death-1 therapy
Shahneen Sandhu, Victoria Atkinson, Maria González Cao, et al.
Molecular Cancer
|
October 11, 2024
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response
Su Yin Lim, Ines Pires da Silva, Nurudeen A Adegoke, et al.
Clinical and Experimental Dermatology
|
April 18, 2022
Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge and behaviour of Australian high-school students towards sun safety: a prospective study
Sarah Hanna, Emmanuel Marinos, Derek Bryan, et al.
Histopathology
|
December 28, 2018
Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment
Tuba N Gide, Benjamin M Allanson, Alexander M Menzies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
Georgina V Long, Alexander M Menzies, Adnan M Nagrial, et al.
Page
of 71